Accumulation of plasma advanced oxidation protein products(AOPPs) promotes progression of proteinuria and glomerulo-sclerosis.To investigate the molecular basis of AOPPs-induced proteinuria,normal Sprague-Dawley rats ...Accumulation of plasma advanced oxidation protein products(AOPPs) promotes progression of proteinuria and glomerulo-sclerosis.To investigate the molecular basis of AOPPs-induced proteinuria,normal Sprague-Dawley rats were treated with AOPPs-modified rat serum albumin.The expression of glomerular podocyte slit diaphragm(PSD)-associated proteins,nephrin and podocin,was significantly decreased coincident with the onset of albuminuria in rats treated with AOPPs.Chronic inhibi-tion of NADPH oxidase by apocynin prevented down-regulation of nephrin and podocin and decreased albuminuria in AOPPs-challenged rats.This suggested that accumulation of AOPPs promotes proteinuria,possibly via down-regulating the expression of PSD-associated proteins.展开更多
Background Advanced oxidation protein products （AOPPs） are new uremic toxins reported by Witko-Sarsat in 1996, which are associated with the pathogenesis of atherosclerosis. However, the mechanisms by which AOPPs en...Background Advanced oxidation protein products （AOPPs） are new uremic toxins reported by Witko-Sarsat in 1996, which are associated with the pathogenesis of atherosclerosis. However, the mechanisms by which AOPPs enhance atherosclerosis have not been fully understood. Monocyte chemoattractant protein-1 （MCP-1） is a chemokine which stimulates migration of monocytes and plays a critical role in the development of atherosclerosis. In this study, we investigated the effect of AOPPs on MCP-1 expression in cultured vascular smooth muscle cells （VSMCs）.展开更多
目的:观察针药并用对糖尿病肾病脾肾气虚挟痰瘀证患者氧化应激水平的影响。方法:116例糖尿病肾病脾肾气虚挟痰瘀证患者按照随机数字表法分为对照组和观察组各58例。对照组患者给予厄贝沙坦片口服,观察组给予针药综合疗法,1周为1个疗程,...目的:观察针药并用对糖尿病肾病脾肾气虚挟痰瘀证患者氧化应激水平的影响。方法:116例糖尿病肾病脾肾气虚挟痰瘀证患者按照随机数字表法分为对照组和观察组各58例。对照组患者给予厄贝沙坦片口服,观察组给予针药综合疗法,1周为1个疗程,两组均连续治疗8个疗程。比较两组患者临床疗效,观察患者治疗前后血糖、血脂及肾功能各指标水平变化,检测治疗前后患者血清超氧化物歧化酶(superoxide dismutase,SOD)、晚期糖基化终末产物(advanced glycosylation end products,AGE)、晚期氧化蛋白产物(advanced oxidation protein products,AOPP)、丙二醛(malondialdehyde,MDA)水平变化。结果:观察组的有效率为91.3%高于对照组的75.9%(χ2=5.098,P<0.05)。治疗后,观察组患者的血糖、血脂及肾功能改善优于对照组,其各指标水平显著低于对照组患者(P<0.05);观察组患者经治疗后SOD活性显著高于对照组患者,而AGE、AOPP、MDA水平则显著低于对照组患者(P<0.05)。结论:针药并用治疗糖尿病肾病患者疗效肯定,利于改善患者的糖脂代谢,提高肾功能,其机制与增强SOD活性、清除AGE、AOPP、MDA以减轻患者的氧化应激损伤有关。展开更多
基金supported by the National Natural Science Foundation of China (Grant Nos 30830056 and 30830056)the National Basic Research Program of China (Grant No 2006CB503904) to Dr HOU FanFan+1 种基金the National Natural Science Foundation of China (Grant No 30971382)the Natural Science Foundation of Guangdong Province (Grant No 06024402) to Dr LIANG Min
文摘Accumulation of plasma advanced oxidation protein products(AOPPs) promotes progression of proteinuria and glomerulo-sclerosis.To investigate the molecular basis of AOPPs-induced proteinuria,normal Sprague-Dawley rats were treated with AOPPs-modified rat serum albumin.The expression of glomerular podocyte slit diaphragm(PSD)-associated proteins,nephrin and podocin,was significantly decreased coincident with the onset of albuminuria in rats treated with AOPPs.Chronic inhibi-tion of NADPH oxidase by apocynin prevented down-regulation of nephrin and podocin and decreased albuminuria in AOPPs-challenged rats.This suggested that accumulation of AOPPs promotes proteinuria,possibly via down-regulating the expression of PSD-associated proteins.
文摘Background Advanced oxidation protein products （AOPPs） are new uremic toxins reported by Witko-Sarsat in 1996, which are associated with the pathogenesis of atherosclerosis. However, the mechanisms by which AOPPs enhance atherosclerosis have not been fully understood. Monocyte chemoattractant protein-1 （MCP-1） is a chemokine which stimulates migration of monocytes and plays a critical role in the development of atherosclerosis. In this study, we investigated the effect of AOPPs on MCP-1 expression in cultured vascular smooth muscle cells （VSMCs）.
文摘目的:观察针药并用对糖尿病肾病脾肾气虚挟痰瘀证患者氧化应激水平的影响。方法:116例糖尿病肾病脾肾气虚挟痰瘀证患者按照随机数字表法分为对照组和观察组各58例。对照组患者给予厄贝沙坦片口服,观察组给予针药综合疗法,1周为1个疗程,两组均连续治疗8个疗程。比较两组患者临床疗效,观察患者治疗前后血糖、血脂及肾功能各指标水平变化,检测治疗前后患者血清超氧化物歧化酶(superoxide dismutase,SOD)、晚期糖基化终末产物(advanced glycosylation end products,AGE)、晚期氧化蛋白产物(advanced oxidation protein products,AOPP)、丙二醛(malondialdehyde,MDA)水平变化。结果:观察组的有效率为91.3%高于对照组的75.9%(χ2=5.098,P<0.05)。治疗后,观察组患者的血糖、血脂及肾功能改善优于对照组,其各指标水平显著低于对照组患者(P<0.05);观察组患者经治疗后SOD活性显著高于对照组患者,而AGE、AOPP、MDA水平则显著低于对照组患者(P<0.05)。结论:针药并用治疗糖尿病肾病患者疗效肯定,利于改善患者的糖脂代谢,提高肾功能,其机制与增强SOD活性、清除AGE、AOPP、MDA以减轻患者的氧化应激损伤有关。
